CN114470304A - Chemoembolization composition and application thereof - Google Patents
Chemoembolization composition and application thereof Download PDFInfo
- Publication number
- CN114470304A CN114470304A CN202111633590.8A CN202111633590A CN114470304A CN 114470304 A CN114470304 A CN 114470304A CN 202111633590 A CN202111633590 A CN 202111633590A CN 114470304 A CN114470304 A CN 114470304A
- Authority
- CN
- China
- Prior art keywords
- phase
- composition
- chemoembolization
- oil
- chemoembolization composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 93
- 230000010109 chemoembolization Effects 0.000 title claims abstract description 67
- 230000010102 embolization Effects 0.000 claims abstract description 41
- 239000000839 emulsion Substances 0.000 claims abstract description 20
- 239000002131 composite material Substances 0.000 claims abstract description 17
- 239000007864 aqueous solution Substances 0.000 claims abstract description 10
- 239000004094 surface-active agent Substances 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 claims description 7
- 229940041181 antineoplastic drug Drugs 0.000 claims description 6
- 229960001025 iohexol Drugs 0.000 claims description 3
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 229960004359 iodixanol Drugs 0.000 claims description 2
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 claims description 2
- 229960004647 iopamidol Drugs 0.000 claims description 2
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 238000002512 chemotherapy Methods 0.000 abstract description 5
- 239000012567 medical material Substances 0.000 abstract description 2
- 239000012071 phase Substances 0.000 description 101
- 239000000499 gel Substances 0.000 description 31
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 7
- 238000001879 gelation Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 239000002872 contrast media Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000003073 embolic effect Effects 0.000 description 5
- 239000004005 microsphere Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000009991 scouring Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000009969 flowable effect Effects 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 description 2
- 235000010958 polyglycerol polyricinoleate Nutrition 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical group OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000010108 arterial embolization Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- WDFKEEALECCKTJ-UHFFFAOYSA-N n-propylprop-2-enamide Chemical compound CCCNC(=O)C=C WDFKEEALECCKTJ-UHFFFAOYSA-N 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003996 polyglycerol polyricinoleate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111633590.8A CN114470304B (en) | 2021-12-28 | 2021-12-28 | Chemoembolization composition and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111633590.8A CN114470304B (en) | 2021-12-28 | 2021-12-28 | Chemoembolization composition and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114470304A true CN114470304A (en) | 2022-05-13 |
CN114470304B CN114470304B (en) | 2023-03-21 |
Family
ID=81495122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111633590.8A Active CN114470304B (en) | 2021-12-28 | 2021-12-28 | Chemoembolization composition and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114470304B (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130022545A1 (en) * | 2011-07-18 | 2013-01-24 | Research & Business Foundation Sungkyunkwan University | DRUG DELIVERY SYSTEM FOR TREATMENT OF LIVER CANCER BASED ON INTERVENTIONAL INJECTION OF TEMPERATURE AND pH-SENSITIVE HYDROGEL |
CN103977413A (en) * | 2014-05-19 | 2014-08-13 | 东南大学 | Developable composite microsphere embolization agent and preparation method thereof |
US20150359885A1 (en) * | 2014-06-12 | 2015-12-17 | Jen-Jie Chieh | Thermal therapeutic reagent |
CN108721684A (en) * | 2018-05-31 | 2018-11-02 | 山东省科学院能源研究所 | Hud typed prepackage chemotherapeutics embolism microball of one kind and preparation method thereof |
WO2019074258A1 (en) * | 2017-10-12 | 2019-04-18 | 서강대학교 산학협력단 | Composition for transcatheter arterial chemoembolization, comprising nanoparticle for anticancer therapy and gene therapy |
CN109663145A (en) * | 2018-12-21 | 2019-04-23 | 太阳雨林(厦门)生物医药有限公司 | A kind of lipiodol targeted drug compound |
US20210353758A1 (en) * | 2019-02-19 | 2021-11-18 | Industry Foundation Of Chonnam National University | Microcarrier for embolization and preparation method therefor |
-
2021
- 2021-12-28 CN CN202111633590.8A patent/CN114470304B/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130022545A1 (en) * | 2011-07-18 | 2013-01-24 | Research & Business Foundation Sungkyunkwan University | DRUG DELIVERY SYSTEM FOR TREATMENT OF LIVER CANCER BASED ON INTERVENTIONAL INJECTION OF TEMPERATURE AND pH-SENSITIVE HYDROGEL |
CN103977413A (en) * | 2014-05-19 | 2014-08-13 | 东南大学 | Developable composite microsphere embolization agent and preparation method thereof |
US20150359885A1 (en) * | 2014-06-12 | 2015-12-17 | Jen-Jie Chieh | Thermal therapeutic reagent |
WO2019074258A1 (en) * | 2017-10-12 | 2019-04-18 | 서강대학교 산학협력단 | Composition for transcatheter arterial chemoembolization, comprising nanoparticle for anticancer therapy and gene therapy |
CN108721684A (en) * | 2018-05-31 | 2018-11-02 | 山东省科学院能源研究所 | Hud typed prepackage chemotherapeutics embolism microball of one kind and preparation method thereof |
CN109663145A (en) * | 2018-12-21 | 2019-04-23 | 太阳雨林(厦门)生物医药有限公司 | A kind of lipiodol targeted drug compound |
US20210353758A1 (en) * | 2019-02-19 | 2021-11-18 | Industry Foundation Of Chonnam National University | Microcarrier for embolization and preparation method therefor |
Non-Patent Citations (1)
Title |
---|
HAN LI ET AL: "pickering gel emulsion of lipiodol stabilized by hairy nanogels for in traartery embolization antitumor therapy", 《CHEMICAL ENGINEERING JOURNAL》 * |
Also Published As
Publication number | Publication date |
---|---|
CN114470304B (en) | 2023-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200268789A1 (en) | Polymeric treatment compositions | |
Zhao et al. | Permanent and peripheral embolization: temperature‐sensitive p (N‐Isopropylacrylamide‐co‐butyl methylacrylate) nanogel as a novel blood‐vessel‐embolic material in the interventional therapy of liver tumors | |
US7001616B2 (en) | Microspheres for use in the treatment of cancer | |
CN102988274B (en) | Sustained-release blood vessel embolic gel used for treating tumor, and preparation method thereof | |
WO2015179997A1 (en) | Polyhydroxyl polymer embolic microsphere and preparation process therefor | |
CN106334213B (en) | A kind of vascular suppository material, preparation method and the purposes in medicine preparation | |
BR112015008245B1 (en) | POLYMERIC TREATMENT COMPOSITIONS | |
CN103239730B (en) | Medical sodium alginate gel microsphere and preparation method and application thereof | |
CN101690831A (en) | Temperature-sensitive nano-gel vascular embolic materials, preparation method and application thereof | |
Park et al. | Design and characterisation of doxorubicin-releasing chitosan microspheres for anti-cancer chemoembolisation | |
US10894110B2 (en) | Developable hyaluronic acid microspherical embolic agent, preparation method and use thereof | |
US10406257B2 (en) | Oily compositions | |
CN105148327B (en) | A kind of preparation method of polysaccharide-Polyvinyl Alcohol Embolization microballoon | |
Qiu et al. | Synthesis and characterization of magnetic polyvinyl alcohol (PVA) hydrogel microspheres for the embolization of blood vessel | |
Vogt et al. | Microfluidic fabrication of imageable and resorbable polyethylene glycol microspheres for catheter embolization | |
CN114470304B (en) | Chemoembolization composition and application thereof | |
CN114099764B (en) | Preparation method of W/O/W type temperature-sensitive embolic agent | |
Xie et al. | A thermosensitive Pickering gel emulsion with a high oil–water ratio for long-term X-ray imaging and permanent embolization of arteries | |
CN105693920A (en) | Preparation method of long-term-development in-situ-gelation temperature-sensitive liquid embolic material | |
Hu et al. | Temperature-responsive hydrogel for tumor embolization therapy | |
CN114853953A (en) | Temperature-sensitive intelligent hydrogel for local injection administration of directionally conveyed stem cells and preparation method and application thereof | |
CN114377192B (en) | Preparation method of embolism material | |
Chimisso et al. | Metal cation responsive anionic microgels: behaviour towards biologically relevant divalent and trivalent ions | |
Rana et al. | Emerging polymer materials in trackable endovascular embolization and cell delivery: from hype to hope | |
Hu et al. | Investigation of the Physical Properties and Clinical Application of Embosphere Microspheres |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230809 Address after: 510700 Room 202, building D, No. 136, Kaiyuan Avenue, Huangpu District, Guangzhou City, Guangdong Province Patentee after: Guangdong Guangna Technology Development Co.,Ltd. Patentee after: Guangzhou Anbo Consulting Partnership (L.P.) Address before: 510535 Room 201, building D, 136 Kaiyuan Avenue, Huangpu District, Guangzhou City, Guangdong Province Patentee before: Guangdong Guangdong Guangdong Hong Kong Macao Dawan District National Nanotechnology Innovation Research Institute |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231121 Address after: 510700 room 1003, building D, No. 136, Kaiyuan Avenue, Huangpu District, Guangzhou City, Guangdong Province Patentee after: Guangdong Guangna Anyu Technology Co.,Ltd. Address before: 510700 Room 202, building D, No. 136, Kaiyuan Avenue, Huangpu District, Guangzhou City, Guangdong Province Patentee before: Guangdong Guangna Technology Development Co.,Ltd. Patentee before: Guangzhou Anbo Consulting Partnership (L.P.) |